A comprehensive research overview of MK-677 (Ibutamoren) — the oral growth hormone secretagogue. Covers mechanism, dosage, 24-hour half-life, IGF-1 elevation, and comparison with injectable GH secretagogues.

Sleep stage overview, GH pulse research during slow-wave sleep, what disrupts recovery, and peptide and supplement interventions including DSIP and Epitalon.

How CJC-1295 + Ipamorelin produce synergistic GH pulses, MK-677 as oral alternative, and sleep timing protocols for GH optimization research.

Comparing GHRH analogs and GHRPs to recombinant HGH: mechanisms, half-lives, pulsatile release, and why researchers choose secretagogues.

Ipamorelin dosage guide: 100–300 mcg dosing, reconstitution table for 2mg and 5mg vials, half-life ~2 hours, pulsatile GH mechanism, and CJC-1295 stack context.

Why CJC-1295 and Ipamorelin are almost always used together — GHRH + GHRP synergy, individual mechanisms, reconstitution math for two vials, and typical research dosing protocols.

Hexarelin research overview: strongest GHRP by potency, desensitization timeline vs GHRP-2 and GHRP-6, typical research doses, reconstitution notes, and protocol considerations.

IGF-1 LR3 vs IGF-1 DES comparison: receptor affinity differences, tissue targeting, reconstitution solvents (acetic acid for both), half-life, and which variant fits which research protocol.

GHRP-2 vs GHRP-6 side-by-side: GH release potency, cortisol and prolactin differences, desensitization rates, typical research doses, and reconstitution calculator.

MK-677 research dosing guide: oral GH secretagogue mechanism, GH pulse data, dose range (10–25 mg/day), half-life timing, and half-life calculator for protocol optimization.

Sermorelin research dosing overview: GHRH analog mechanism, typical dose ranges, reconstitution math for common vial sizes, half-life, and CJC-1295 comparison.